Cargando…

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection

Background During SARS-CoV-2 pandemic, the anticoagulant management in patients with atrial fibrillation (AF) was simplified to the use of low molecular weight heparin (LMWH) in different international guidelines. These recommendations were based for the possible drug interactions between oral antic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olivera, Pável E, Campoy, Desiree, Velasquez, César A, Flores, Katia, Canals, Tania, Johansson, Erik A, Martinez, Laia, Sierra, Jorge, Cerezo, Juan Jose, Salinas, Ramón
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	332.Anticoagulation and Antithrombotic Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330256/ http://dx.doi.org/10.1182/blood-2020-143065

Ejemplares similares

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality
por: Cerezo Manchado, Juan Jose, et al.
Publicado: (2020)

The Impact of Different Prophylactic Anticoagulation Doses on the Outcomes of Patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2020)

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
por: Ashraf, Farah, et al.
Publicado: (2020)

Optimal Anticoagulant Dosing in Patients with COVID-19, a Retrospective Review
por: Carrillo, Alessandra, et al.
Publicado: (2021)

Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients
por: Ionescu, Filip, et al.
Publicado: (2020)

The Potential Role of Therapeutic Dose of Low Molecular Weight Heparin (LWMH) to Attenuate Hyper-Inflammatory State in Hospitalized COVID-19 Patients
por: Mughal, Mohsin Sheraz, et al.
Publicado: (2020)

Anticoagulation Management and Outcomes in Covid-19 Patients:a Multi-Center Retrospective Cohort Study
por: Kaur, Jasmeet, et al.
Publicado: (2020)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

COVID-19-Associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults with COVID-19
por: Chambers, Isaac, et al.
Publicado: (2020)

Clinical Outcomes in Critically-Ill Patients with COVID-19 Treated with Therapeutic Dose of Anticoagulants for Suspected Thromboembolism
por: Naing, Phyu Thin, et al.
Publicado: (2021)

Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
por: Goshua, George, et al.
Publicado: (2020)

COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy
por: Daughety, Molly, et al.
Publicado: (2020)

Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group
por: Moraleda, Jose M., et al.
Publicado: (2020)

Thrombotic Complications in a Canadian Population of Critically Ill Patients with COVID-19
por: Camille, Simard, et al.
Publicado: (2020)

Filter Clotting with Continuous Renal Replacement Therapy in COVID-19
por: Rosovsky, Rachel P., et al.
Publicado: (2020)

The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19
por: Bhoopat, Lantarima, et al.
Publicado: (2020)

Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation
por: Kodama, Rich, et al.
Publicado: (2020)

Targeting the Endothelium in the Treatment of COVID-19 Early Clinical Stages: Results of a Randomized Placebo-Controlled Trial
por: Gonzalez-Ochoa, Alejandro
Publicado: (2021)

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome
por: Yanik, Gregory A, et al.
Publicado: (2021)

Extended Thromboprophylaxis in Patients with COVID-19
por: Zhao, Wei, et al.
Publicado: (2021)

Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial
por: Ruggeri, Annalisa, et al.
Publicado: (2021)

Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation
por: Olivera, Pável, et al.
Publicado: (2023)

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
por: Tun, Han Naung, et al.
Publicado: (2022)

Rapid ECMO Training for Nurses in Response to the COVID-19 Pandemic
por: Toy, B., et al.
Publicado: (2021)

Perioperative Anticoagulation Management in Spine Surgery: Initial Findings From the AO Spine Anticoagulation Global Survey
por: Louie, Philip, et al.
Publicado: (2020)

Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)
por: Guo, X Y, et al.
Publicado: (2023)

IMMUNE THROMBOCYTOPENIA PURPURA FLARE POST SARS-COV-2 VACCINATION
por: Ali, Elrazi, et al.
Publicado: (2021)

Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry
por: Cerezo Manchado, Juan José, et al.
Publicado: (2023)

Use of Edoxaban for the Treatment of Heparin-Induced Thrombocytopenia
por: Kanamoto, Ryo, et al.
Publicado: (2020)

Omitting transesophageal echocardiography before catheter ablation of atrial fibrillation or left sided atrial tachycardia in patients on oral anticoagulation
por: Maslova, V, et al.
Publicado: (2023)

Optimal anticoagulation intensity with warfarin for the prevention of thromboembolism with minimal bleeding in Asian patients with atrial fibrillation: multi-center, randomized controlled trial
por: Lee, K H, et al.
Publicado: (2023)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study
por: Grymonprez, M, et al.
Publicado: (2023)

Impact of concomitant proton pump inhibitor during oral anticoagulant treatment
por: Lee, K N, et al.
Publicado: (2023)

Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study
por: Santoro, F, et al.
Publicado: (2023)

Long-term effectiveness and safety of non-vitamin K antagonist anticoagulant in real world practice
por: Roh, S Y, et al.
Publicado: (2023)

How good is time-in-therapeutic-range defined warfarin treatment compared to standard dose direct oral anticoagulants? Incidence of stroke in atrial fibrillation in a nationwide registry study
por: Lehto, M, et al.
Publicado: (2023)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion
por: Martin, Anne-Céline, et al.
Publicado: (2023)

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban
por: Ansell, Jack E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6si2us3va7u1jb2smse9qlp482